Mycophenolate-induced colitis in a patient with lupus nephritis: a case report and review of the literature.
Case report
Colitis
MMF
Mycophenolate mofetil
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
received:
30
08
2023
accepted:
05
04
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
Mycophenolate mofetil (MMF) is an immunosuppressive drug that is frequently prescribed to patients with rheumatological diseases. MMF's side effects include abdominal discomfort, nausea, vomiting, and other gastro-intestinal side effects, which typically appear in the first few months of treatment. However, late-onset diarrhea does not rule out the presence of MMF-induced colitis, which can be misdiagnosed since it is linked to a broad range of histopathological characteristics, including alterations that resemble inflammatory bowel disease, graft-versus-host disease, and ischemia. The differences in treatment response may be explained by the complexity of the histopathologic characteristics. Here we present a case of a 29-year-old Arabian female with lupus nephritis who started on MMF as induction therapy. In two months, the patient was presented to the Emergency Department with diarrhea and manifestations of severe dehydration. Infectious diseases and adverse drug events were suspected, so the patient was admitted for further workup, and MMF was stopped. The patient was diagnosed with MMF-induced colitis based on colonoscopy and histological findings. Fourteen days after stopping MMF, she was within her baseline. The purpose of this paper is to report a case of early-onset MMF-induced colitis in a patient with lupus nephritis who had started MMF as induction therapy. A review of the available literature on this uncommon immunosuppressive effect is also presented.
Sections du résumé
BACKGROUND
BACKGROUND
Mycophenolate mofetil (MMF) is an immunosuppressive drug that is frequently prescribed to patients with rheumatological diseases. MMF's side effects include abdominal discomfort, nausea, vomiting, and other gastro-intestinal side effects, which typically appear in the first few months of treatment. However, late-onset diarrhea does not rule out the presence of MMF-induced colitis, which can be misdiagnosed since it is linked to a broad range of histopathological characteristics, including alterations that resemble inflammatory bowel disease, graft-versus-host disease, and ischemia. The differences in treatment response may be explained by the complexity of the histopathologic characteristics.
CASE PRESENTATION
METHODS
Here we present a case of a 29-year-old Arabian female with lupus nephritis who started on MMF as induction therapy. In two months, the patient was presented to the Emergency Department with diarrhea and manifestations of severe dehydration. Infectious diseases and adverse drug events were suspected, so the patient was admitted for further workup, and MMF was stopped. The patient was diagnosed with MMF-induced colitis based on colonoscopy and histological findings. Fourteen days after stopping MMF, she was within her baseline.
CONCLUSION
CONCLUSIONS
The purpose of this paper is to report a case of early-onset MMF-induced colitis in a patient with lupus nephritis who had started MMF as induction therapy. A review of the available literature on this uncommon immunosuppressive effect is also presented.
Identifiants
pubmed: 38689344
doi: 10.1186/s13256-024-04539-7
pii: 10.1186/s13256-024-04539-7
doi:
Substances chimiques
Mycophenolic Acid
HU9DX48N0T
Immunosuppressive Agents
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
229Informations de copyright
© 2024. The Author(s).
Références
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118. https://doi.org/10.1016/s0162-3109(00)00188-0 .
doi: 10.1016/s0162-3109(00)00188-0
pubmed: 10878285
Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996;10(1 Pt 2):77–84.
pubmed: 8680053
Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant. 2005;19(6):779–84. https://doi.org/10.1111/j.1399-0012.2005.00421.x .
doi: 10.1111/j.1399-0012.2005.00421.x
pubmed: 16313325
Isaacs PE, Sladen GE, Filipe I. Mefenamic acid enteropathy. J Clin Pathol. 1987;40(10):1221–7. https://doi.org/10.1136/jcp.40.10.1221 .
doi: 10.1136/jcp.40.10.1221
pubmed: 3680546
pmcid: 1141199
Gioco R, Puzzo L, Patanè M, Corona D, Trama G, Veroux P, Veroux M. Post-transplant colitis after kidney transplantation: clinical, endoscopic and histological features. Aging (Albany NY). 2020;12(24):24709–20. https://doi.org/10.18632/aging.202345 .
doi: 10.18632/aging.202345
pubmed: 33353887
pmcid: 7803550
Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J, Bhamidimarri KR. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol. 2015;28(3):366–73.
pubmed: 26126799
pmcid: 4480174
Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly. 2009;139(3–4):41–6. https://doi.org/10.4414/smw.2009.12441 .
doi: 10.4414/smw.2009.12441
pubmed: 19169902
Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014;24(1):73–9.
doi: 10.1097/FPC.0000000000000010
pubmed: 24220207
pmcid: 4091813
Md Dom ZI, Coller JK, Carroll RP, Tuke J, McWhinney BC, Somogyi AA, et al. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. Br J Clin Pharmacol. 2018;84(10):2433–42.
doi: 10.1111/bcp.13704
pubmed: 29974488
pmcid: 6138476
Lee S, de Boer WB, Subramaniam K, Kumarasinghe MP. Pointers and pitfalls of mycophenolate-associated colitis. J Clin Pathol. 2013;66(1):8–11. https://doi.org/10.1136/jclinpath-2012-200888 .
doi: 10.1136/jclinpath-2012-200888
pubmed: 23038687
Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis.
Selbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. 2009;22(6):737–43. https://doi.org/10.1038/modpathol.2009.44 .
doi: 10.1038/modpathol.2009.44
pubmed: 19329937
Mycophenolate mofetil-induced colitis with graft versus host disease-like features in a renal transplant recipient: case report and literature review.
Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol. 2008;32(9):1367–72. https://doi.org/10.1097/pas.0b013e31816bf3fe .
doi: 10.1097/pas.0b013e31816bf3fe
pubmed: 18763324
Al Saadi W, Al Salmi I, Mohammed E, Al Ajmi Z, Hannawi S. Mycophenolate induced colitis: one-year post-kidney transplantation. Oman Med J. 2023;38(2): e489. https://doi.org/10.5001/omj.2023.14 .
doi: 10.5001/omj.2023.14
pubmed: 37132007
pmcid: 10148970
Schmitt MM, Ferré EMN, De Melo MS, Cooper MA, Quezado MM, Heller T, Lionakis MS. Mycophenolate-induced colitis in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. JPGN Rep. 2021;2(4): e131. https://doi.org/10.1097/pg9.0000000000000131 .
doi: 10.1097/pg9.0000000000000131
pubmed: 35425944
pmcid: 9004485
Bani Fawwaz BA, Aldwairy A, Farooq A. Mycophenolate-induced colitis: a rare side effect. Cureus. 2021;13(9): e18250. https://doi.org/10.7759/cureus.18250 .
doi: 10.7759/cureus.18250
pubmed: 34712529
pmcid: 8542390
Farooqi R, Kamal A, Burke C. Mycophenolate-induced colitis: a case report with focused review of literature. Cureus. 2020;12(1): e6774. https://doi.org/10.7759/cureus.6774 .
doi: 10.7759/cureus.6774
pubmed: 32117661
pmcid: 7041651
Tayyem O, Saraireh H, Al Hanayneh M, Stevenson HL. Heart transplant recipient with mycophenolate mofetil-induced colitis: the great imitator. BMJ Case Rep. 2018;2018:bcr2017224035. https://doi.org/10.1136/bcr-2017-224035 .
doi: 10.1136/bcr-2017-224035
pubmed: 29930181
pmcid: 6020965
Moroncini G, Benfaremo D, Mandolesi A, Gabrielli A. Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis. BMJ Case Rep. 2018;2018:bcr2018224829. https://doi.org/10.1136/bcr-2018-224829 .
doi: 10.1136/bcr-2018-224829
pubmed: 29776943
pmcid: 5965754
Sonoda A, Wada K, Mizukami K, Fukuda K, Shuto M, Okamoto K, Ogawa R, Okimoto T, Murakami K. Deep ulcers in the ileum associated with mycophenolate mofetil. Intern Med. 2017;56(21):2883–6. https://doi.org/10.2169/internalmedicine.8815-17 .
doi: 10.2169/internalmedicine.8815-17
pubmed: 28943566
pmcid: 5709631
Dhakal P, Gami R, Giri S, Bhatt VR. Mycophenolate mofetil (MMF)-induced colitis. Blood. 2016;128:4795.
doi: 10.1182/blood.V128.22.4795.4795
Goyal A, Salahuddin M, Govil Y. A unique case of mycophenolate induced colitis after 10 years of use. Case Rep Gastrointest Med. 2016;2016:3058407. https://doi.org/10.1155/2016/3058407 .
doi: 10.1155/2016/3058407
pubmed: 27668102
pmcid: 5030415
Johal K, Ratuapli SK, Lam-Himlin DM, Gurudu SR. Mycophenolate mofetil-induced segmental colitis mimicking ischemic colitis. Case Rep Gastroenterol. 2014;8(1):95–100. https://doi.org/10.1159/000360847 .
doi: 10.1159/000360847
pubmed: 24803893
pmcid: 3999574
Hamouda M, Mahmoudi H, Skhiri H, Elmay M. Mycophenolate mofetil-related pancolitis in a kidney transplant recipient [published correction appears in Exp Clin Transplant. 2012 Aug;10(4):418]. Exp Clin Transplant. 2012;10(5):501–5. https://doi.org/10.6002/ect.2011.0200 .
doi: 10.6002/ect.2011.0200
pubmed: 22554227
Patra S, Vij M, Sukanya B, Kapoor D. Mycophenolate mofetil-induced colitis with graft versus host disease-like features in a liver transplant recipient. Indian J Pathol Microbiol. 2012;55(4):506–8. https://doi.org/10.4103/0377-4929.107792 .
doi: 10.4103/0377-4929.107792
pubmed: 23455789
Gorospe EC. Chronic diarrhoea from mycophenolate mofetil-induced colitis. BMJ Case Rep. 2012;2012:bcr2220115344. https://doi.org/10.1136/bcr.12.2011.5344 .
doi: 10.1136/bcr.12.2011.5344
Bouhbouh S, Rookmaaker MB. Rapid resolution of persistent mycophenolate mofetil-induced diarrhoea with a single dose of infliximab. Nephrol Dial Transplant. 2010;25(10):3437–8. https://doi.org/10.1093/ndt/gfq379 .
doi: 10.1093/ndt/gfq379
pubmed: 20615909